Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 8;12:747594. doi: 10.3389/fimmu.2021.747594

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Ispasanie, Muri, Schubart, Thorburn, Zamurovic, Holbro, Kammüller and Pluschke

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Cumulative comparative analysis of the effect of complement inhibitors on the survival of meningococci in pre- and post-vaccination sera. The percent survival of the three technical replicates of the effect of inhibitors on all meningococcal isolates and subjects were pooled as pre-, 2 weeks (w) and 2 months (m) post-vaccination. The horizontal dotted line represents 50% survival of bacteria after 60 min incubation. fB indicates factor B inhibitor Iptacopan; fD, factor D inhibitor CMS487; C3, C3 inhibitor CP-40; C5, anti-C5 mAb Tesidolumab; MASP-2, anti-MASP-2 mAb Narsoplimab.